Innate Pharma S.A. (IPHA)

NASDAQ: IPHA · Real-Time Price · USD
2.200
+0.060 (2.80%)
May 29, 2025, 4:00 PM - Market closed
2.80%
Market Cap 207.54M
Revenue (ttm) 20.83M
Net Income (ttm) -51.22M
Shares Out 92.16M
EPS (ttm) -0.63
PE Ratio n/a
Forward PE 1.69
Dividend n/a
Ex-Dividend Date n/a
Volume 10,752
Open 2.200
Previous Close 2.140
Day's Range 2.122 - 2.240
52-Week Range 1.290 - 3.511
Beta 0.94
Analysts Strong Buy
Price Target 11.00 (+400.0%)
Earnings Date Mar 27, 2025

About IPHA

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 17, 2019
Employees 181
Stock Exchange NASDAQ
Ticker Symbol IPHA
Full Company Profile

Financial Performance

In 2024, Innate Pharma's revenue was 20.12 million, a decrease of -67.36% compared to the previous year's 61.64 million. Losses were -49.47 million, 553.5% more than in 2023.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to one analyst, the rating for IPHA stock is "Strong Buy" and the 12-month stock price forecast is $11.0.

Price Target
$11.0
(400.00% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

MARSEILLE, France--(BUSINESS WIRE)-- #IRConferences--Innate Pharma announces its participation in upcoming investor conferences.

2 days ago - Business Wire

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of long-term fol...

6 days ago - Business Wire

Outcome of Innate Pharma's 2025 Annual General Meeting

MARSEILLE, France--(BUSINESS WIRE)-- #AG--Outcome of Innate Pharma's 2025 Annual General Meeting.

6 days ago - Business Wire

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate's drugs i...

10 days ago - Business Wire

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH6501, its A...

14 days ago - Business Wire

Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Corporate Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - Chief Executive Officer...

16 days ago - Seeking Alpha

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the q...

16 days ago - Business Wire

Innate Pharma announces conference call and webcast for Q1 2025 business update

MARSEILLE, France--(BUSINESS WIRE)-- #innatepharma--Innate Pharma announces conference call and webcast for Q1 2025 business update.

23 days ago - Business Wire

Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2024 Universal Registra...

4 weeks ago - Business Wire

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

MARSEILLE, France--(BUSINESS WIRE)-- #AACR--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today shared new preclinical data for IPH4502, its novel a...

4 weeks ago - Business Wire

Innate Pharma Announces €15M Investment by Sanofi

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces a €14,999,998.59 capital increase subscri...

5 weeks ago - Business Wire

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announce review of their January 2016 Research Coll...

5 weeks ago - Business Wire

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma proposes to its shareholders to transform its corporate governance structure into a board of directors and to change its composition.

6 weeks ago - Business Wire

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to hold its Annual General Meeting of shareholders on May 22, 2025.

6 weeks ago - Business Wire

Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in the 2025 Stifel Virtual Targeted Oncology Forum.

2 months ago - Business Wire

Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2024 Earnings Conference Call March 27, 2025 9:00 AM ET Company Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - CEO Yannis Morel - COO ...

2 months ago - Seeking Alpha

Innate Pharma Reports Full Year 2024 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the y...

2 months ago - Business Wire

Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting

MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH4502, its nov...

2 months ago - Business Wire

Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference.

2 months ago - Business Wire

Innate Pharma: Moving Into The Padcev Space

Innate Pharma's diverse pipeline, including lacutamab, IPH6501, and IPH4502, shows promising clinical activity and potential for significant milestones in 2025. Lacutamab, a key asset, received US FDA...

2 months ago - Seeking Alpha

Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for full year 2024 financial results.

2 months ago - Business Wire

Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in The 2025 Leerink Partners Global Healthcare Conference.

3 months ago - Business Wire

Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion

Positive results achieved in the open-label phase 2 TELLOMAK study, using lacutamab for the treatment of patients with relapsed/refractory Sezary Syndrome; Patients achieved a confirmed Objective Resp...

3 months ago - Seeking Alpha

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary Syndrome.

3 months ago - Business Wire

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its P...

4 months ago - Business Wire